



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Bae Abertawe
Swansea Bay University
Health Board

Cadeirydd/Chair: **Emma Woollett**
Prif Weithredwr/Chief Executive: **Tracy Myhill**

gofalu am ein gilydd, cydweithio, gwella bob amser
caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 9th September 2020
Ein Cyf / Our Ref: 20-H-022

☎ 01639 648363
✉ FOIA.Requests@wales.nhs.uk

Corporate Services
Headquarters
1 Talbot Gateway
Baglan
Port Talbot, SA12 7BR

Dear

I refer to your Freedom of Information Act Request acknowledged by ourselves on 12th August 2020. Your request sought information relating to liver disease.

1. Please enter the name of your Health Board

Swansea Bay University Health Board

2. Do you have a named person within the Health Board who is responsible for liver disease?

Yes

If yes, please answer Q3 and then move to Q5

If no, please answer Q4 and then move to Q5

3. Please provide the details of the person responsible for liver disease within the Health Board

Dr Chinlye Ch'ng

4. In the absence of a named contact for liver disease at the Health Board, please provide the details of the person who should be contacted regarding liver health

Dr Jag Nagaraj



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

- 5. Do you have a commissioned pathway for:**
a) the interpretation of abnormal liver blood tests?
b) responding to liver disease more generally?

Yes, pathways for both

If answer to any of these is yes, please move to Q6

If answer is no pathways for either, please move to Q9

- 6. Does it include an endorsed pathway for the management of abnormal liver blood tests that follow the BSG guidance?**

Yes

- 7. Is liver fibrosis assessment part of your pathway?**

Yes

If yes, please move to Q8

If no, please move to Q9

- 8. Please indicate how fibrosis is assessed.**

Fibroscan (transient elastography)

FIB-4 score

NAFLD fibrosis score

- 9. Do you have an additional pathway that proactively case-finds individuals who may be at high-risk of liver disease? e.g. people with diabetes or for those who drink alcohol at harmful levels**

Yes

If yes, please move to Q10

If no, please move to Q12

- 10. How does your pathway define individuals as high risk of liver disease?**

Diabetes

Alcohol risk

Obesity

Obesity with other metabolic risk factors

Risk factors for viral hepatitis

- 11. How are these individuals identified?**

At annual chronic disease / year of care review

Opportunistically during consultations

- 12. Does the Health Board monitor the breadth of adoption and efficacy of pathways in primary care your area?**

No

- 13. Where are these statistics published?**

Not applicable



14. Are you aware of the current available statistics relating to liver disease in your area and do you monitor these?

No

15. Would you be willing to share your pathway information with other Health Boards for best practice purposes?

Yes

I hope this information is helpful. If you require anything further please contact us at FOIA.Requests@wales.nhs.uk.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via FOIA.Requests@wales.nhs.uk.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



Pam Wenger
Director of Corporate Governance

